Navigation Links
Celladon Corporation Receives Notice of Allowance from European Patent Office
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has received a Notice of Allowance from the European Patent Office (EPO) for claims that cover MYDICAR, Celladon's first in class drug under clinical evaluation for advanced heart failure. The patent to be issued from this allowed patent application, titled "Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy" carries a patent term to at least 2027. A similar application has been filed with the U.S. Patent and Trademark Office (USPTO).

"This is an important addition to our existing patent portfolio. The allowance strengthens our ability to broadly protect our proprietary technology as we continue the clinical development of MYDICAR," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "We will continue to complement our existing patent portfolio to further fortify MYDICAR's market exclusivity position."

About MYDICAR®

MYDICAR® is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling and contractility. SERCA2a levels decline in all forms of late-stage heart failure resulting in deficient heart function. With MYDICAR®, the SERCA2a gene is delivered using a recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR® is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR®  is synergistic and additive across current heart failure treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician.

About Heart Failure

Chronic heart failure is a leading cause of hospitalization and is expected to result in direct and indirect costs of $39.2 billion to the U.S. healthcare system in 2010. Nearly 6 million people in the U.S. have heart failure, and at least 670,000 new cases will be diagnosed this year. Heart failure leads to about 280,000 deaths annually. The most common symptoms of heart failure are shortness of breath, feeling tired and swelling in the ankles, feet, legs and sometimes the abdomen. There is no cure.

 

 


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
3. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
4. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
5. Luminex Corporation Reports First Quarter 2012 Results
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
8. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
11. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Germany ... GlobalData,s new report, "Germany Cataract Surgery Devices Market ... Germany Cataract Surgery Devices market. The report provides value, ... average prices (USD) within market segements - Phacoemulsification Equipment ... provides company shares and distribution shares data for each ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... 20, 2017 , ... “I Forgive You”: a fine examination of how God handles sin, ... creation of published author, Stephen Miller, who, for over ten long years has been waiting ... Born in Trinidad and Tobago, he has been serving the Lord for over twenty years, ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that ... of published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose ... since high school and have many different titles,” Gaapf mentions about his different works. ...
Breaking Medicine News(10 mins):